A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

2001424 citationsJournal Article

Authors

Janet Pope · Western University

Nicholas Bellamy

James R. Seibold · Rutgers, The State University of New Jersey

Murray Baron · Jewish General Hospital

Michael H. Ellman · University of Chicago

Simon Carette · University of Toronto

C. Douglas Smith · University of Ottawa

Abstract

Although results of this trial demonstrated a trend in favor of MTX versus placebo in the treatment of early diffuse SSc, the between-group differences were small and the power to rule out false-negative results was only 50%. Our findings do not provide evidence that MTX is significantly effective in the treatment of early diffuse SSc.

Topics & Keywords

Systemic Sclerosis and Related Diseases Dermatologic Treatments and Research Skin Diseases and Diabetes

Publication Details

Published in: Arthritis & Rheumatism

Volume 44, Issue 6, pp. 1351-1358

DOI: 10.1002/1529-0131(200106)44:6<1351::aid-art227>3.0.co;2-i

Field-Weighted Citation Impact: 5.01

Command Palette

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

Authors

Abstract

Topics & Keywords

Publication Details